These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25187307)

  • 21. VKORC1 and CYP2C9 genotype distribution in Asian countries.
    Gaikwad T; Ghosh K; Shetty S
    Thromb Res; 2014 Sep; 134(3):537-44. PubMed ID: 24908449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.
    Ohara M; Suzuki Y; Shinohara S; Gong IY; Schmerk CL; Tirona RG; Schwarz UI; Wen MS; Lee MTM; Mihara K; Nutescu EA; Perera MA; Cavallari LH; Kim RB; Takahashi H
    Clin Pharmacokinet; 2019 Aug; 58(8):1077-1089. PubMed ID: 30815847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
    Sridharan K; Sivaramakrishnan G
    J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.
    Hamberg AK; Friberg LE; Hanséus K; Ekman-Joelsson BM; Sunnegårdh J; Jonzon A; Lundell B; Jonsson EN; Wadelius M
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1275-83. PubMed ID: 23307232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
    Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
    Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
    Wang F; Guo J; Zhang A
    J Cardiovasc Pharmacol; 2019 Mar; 73(3):127-135. PubMed ID: 30688796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation.
    Huang TS; Zhang L; He Q; Li YB; Dai ZL; Zheng JR; Cheng PQ; He YS
    Australas Phys Eng Sci Med; 2017 Mar; 40(1):249-258. PubMed ID: 28083852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
    Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
    J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
    [No Abstract]   [Full Text] [Related]  

  • 30. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
    Helin TA; Joutsi-Korhonen L; Asmundela H; Niemi M; Orpana A; Lassila R
    Br J Clin Pharmacol; 2019 Aug; 85(8):1684-1691. PubMed ID: 30933373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.
    Sasano M; Ohno M; Fukuda Y; Nonen S; Hirobe S; Maeda S; Miwa Y; Yokoyama J; Nakayama H; Miyagawa S; Sawa Y; Fujio Y; Maeda M
    Eur J Clin Pharmacol; 2019 Jul; 75(7):901-911. PubMed ID: 30852642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of the impact of
    Asari K; Takahashi H
    Pharmacogenomics; 2020 Aug; 21(12):853-862. PubMed ID: 32700644
    [No Abstract]   [Full Text] [Related]  

  • 34. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
    Limdi NA; Wadelius M; Cavallari L; Eriksson N; Crawford DC; Lee MT; Chen CH; Motsinger-Reif A; Sagreiya H; Liu N; Wu AH; Gage BF; Jorgensen A; Pirmohamed M; Shin JG; Suarez-Kurtz G; Kimmel SE; Johnson JA; Klein TE; Wagner MJ;
    Blood; 2010 May; 115(18):3827-34. PubMed ID: 20203262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
    Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients.
    Tanaka T; Ihara M; Fukuma K; Yamamoto H; Washida K; Kimura S; Kada A; Miyata S; Miyata T; Nagatsuka K
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.
    Mandic D; Bozina N; Mandic S; Samardzija M; Milostic-Srb A; Rumora L
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):905-13. PubMed ID: 26445138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
    Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.